Diabetes Research and Clinical Practice
Volume 61 , Pages S19-S26 , July 2003

LDL-cholesterol, HDL-cholesterol or triglycerides—which is the culprit?

References 

  1. Haffner SM, Lehto S, Ronemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl. J. Med. 1998;339:229–234
  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 2001;285:2486–2497
  3. Turner RC, Millns H, Neil HAW, et al.  Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br. Med. J. 1998;316:823–828
  4. Isomaa B, Almgren P, Tuomi T, et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689
  5. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2002;25(Suppl. 1):S74–S77
  6. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care. 2000;23:754–758
  7. Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia. 2002;45:461–475
  8. Evans M, Anderson RA, Graham J, et al.  Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation. 2000;101:1773–1779
  9. Gray RS, Robbins DC, Wang W, et al.  Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler. Thromb. Vasc. Biol. 1997;17:2713–2720
  10. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J. Am. Med. Assoc. 1988;260:1917–1921
  11. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J. Am. Med. Assoc. 1996;276:875–881
  12. Tan KCB, Ai VHG, Chow WS, Chau MT, Leong L, Lam KSL. Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilatation in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 1999;84:3212–3216
  13. Mäkimattila S, Liu M-L, Vakkilainen J, et al.  Impaired endothelium-dependent vasodilatation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care. 1999;22:973–981
  14. Vakkilainen J, Mäkimattila S, Seppälä-Lindroos A, et al.  Endothelial dysfunction in men with small LDL particles. Circulation. 2000;102:716–721
  15. Skoglund-Andersson C, Tang R, Bond MG, de Faire U, Hamsten A, Karpe F. LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. Arterioscler. Thromb. Vasc. Biol. 1999;19:2422–2430
  16. Laakso M, Lehto S, Penttila I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993;88:1421–1430
  17. Syvänne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 1997;350(Suppl. I):20–23
  18. Lamarche B, Uffelman KD, Carpentier A, et al.  Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J. Clin. Invest. 1999;103:1191–1199
  19. Toikka JO, Ahotupa M, Viikari JS. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis. 1999;147:133–138
  20. Spieker LE, Sudano I, Hurlimann D, et al.  High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399–1402
  21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  22. Syvanne M, Vuorinen-Markkola H, Hilden H, Taskinen MR. Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus. Arterioscler. Thromb. 1993;13:286–295
  23. Syvanne M, Hilden H, Taskinen MR. Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. J. Lipid Res. 1994;35:15–26
  24. Alagona C, Soro A, Ylitalo K, Salonen R, Salonen JT, Taskinen MR. A low high density lipoprotein (HDL) level is associated with carotid artery intima-media thickness in asymptomatic members of low HDL families. Atherosclerosis. 2002;165:309–316

PII: S0168-8227(03)00126-8

doi: 10.1016/S0168-8227(03)00126-8

Diabetes Research and Clinical Practice
Volume 61 , Pages S19-S26 , July 2003

Article Tools

* Image Usage & Resolution